Clinical Trial

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2022-02-17; most recent amendment 2025-09-10.
Status change: Recruiting → Active, Not Recruiting 2023-12-15
Status change: Not Yet Recruiting → Recruiting 2022-05-19
Trial Details
NCT Number NCT05246670
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Enrollment 88 participants
Start Date 2022-05-16
Primary Completion 2024-02-12 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-22